TCIM
BMY icon

TIAA CREF Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

TIAA CREF Investment Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$262M Buy
5,493,610
+98,708
+2% +$4.92M 0.19% 111
2018
Q4 		$280M Sell
5,394,902
-1,249,022
-19% -$67.1M 0.22% 92
2018
Q3 		$412M Buy
6,643,924
+598,840
+10% +$35.5M 0.27% 77
2018
Q2 		$335M Sell
6,045,084
-2,881,915
-32% -$156M 0.22% 96
2018
Q1 		$565M Sell
8,926,999
-2,005,723
-18% -$129M 0.38% 57
2017
Q4 		$670M Buy
10,932,722
+2,573,967
+31% +$161M 0.44% 46
2017
Q3 		$533M Buy
8,358,755
+1,394,783
+20% +$81.4M 0.36% 59
2017
Q2 		$388M Sell
6,963,972
-1,457,324
-17% -$79.3M 0.27% 80
2017
Q1 		$458M Sell
8,421,296
-953,579
-10% -$52.3M 0.33% 64
2016
Q4 		$548M Sell
9,374,875
-13,511
-0.1% -$739K 0.41% 49
2016
Q3 		$506K Sell
9,388,386
-2,058,760
-18% -$132M 0.32% 69
2016
Q2 		$842M Buy
11,447,146
+1,075,075
+10% +$76M 0.65% 28
2016
Q1 		$663M Buy
10,372,071
+921,866
+10% +$58.1M 0.51% 41
2015
Q4 		$650M Sell
9,450,205
-1,829
-0% -$121K 0.49% 42
2015
Q3 		$560M Buy
9,452,034
+250,289
+3% +$15.9M 0.44% 48
2015
Q2 		$612M Sell
9,201,745
-603,293
-6% -$39.8M 0.43% 45
2015
Q1 		$632M Sell
9,805,038
-961,016
-9% -$60.2M 0.44% 42
2014
Q4 		$636M Buy
10,766,054
+211,446
+2% +$11.9M 0.44% 42
2014
Q3 		$540M Buy
10,554,608
+526,888
+5% +$26.3M 0.38% 49
2014
Q2 		$486M Sell
10,027,720
-3,582,720
-26% -$177M 0.34% 53
2014
Q1 		$707M Buy
13,610,440
+3,661,143
+37% +$195M 0.51% 36
2013
Q4 		$529M Buy
9,949,297
+600,351
+6% +$30.6M 0.38% 50
2013
Q3 		$433M Sell
9,348,946
-1,114,345
-11% -$48.9M 0.34% 56
2013
Q2 		$468M Buy
+10,463,291
New +$454M 0.38% 50

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TIAA CREF Investment Management's BMY Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Bristol-Myers Squibb (BMY) stake by 1.8% in Q1 2019, buying an estimated $4.92M and bringing the position to 5,493,610 shares worth $262M. The position accounts for 0.19% of the portfolio, ranked #111.

TIAA CREF Investment Management first reported a position in BMY in Q2 2013 and has held it in 24 quarters since. The position peaked at $842M in Q2 2016. 1,813 funds tracked by Wall St. Rank hold BMY as of Q1 2019.

  • TIAA CREF Investment Management held 5,493,610 shares of Bristol-Myers Squibb worth $262M as of Q1 2019.
  • TIAA CREF Investment Management bought 98,708 Bristol-Myers Squibb shares in Q1 2019, an estimated $4.92M.
  • Bristol-Myers Squibb made up 0.19% of TIAA CREF Investment Management's portfolio in Q1 2019, its #111 holding.
  • TIAA CREF Investment Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Bristol-Myers Squibb position peaked at $842M in Q2 2016.
  • 1,813 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.